ASCO GU 2019 - Results from #100

Viewing 101-120 of 154 articles

ASCO GU 2019: Randomized Phase III Trial of Adjuvant Sequential Chemotherapy plus Radiotherapy versus Adjuvant Radiotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: Urothelial Carcinoma Subgroup Analysis.

ASCO GU 2019: Sacituzumab Govitecan (IMMU-132) in Patients with Previously Treated Metastatic Urothelial Cancer

ASCO GU 2019: Challenges of Therapy in Upper-Tract Urothelial Carcinoma

ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC

ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk nmCRPC

ASCO GU 2019: Pembrolizumab Plus Olaparib Treatment for Docetaxel-Pretreated mCRPC Patients - KEYNOTE 365 Cohort A

ASCO GU 2019: Trimodality Therapy is the Best Option for Muscle-Invasive Bladder Cancer

ASCO GU 2019: Interim Analysis of Ibrutinib Plus Paclitaxel for Patients with Metastatic Urothelial Carcinoma Previously Treated with Platinum-Based Chemotherapy

ASCO GU 2019: Fierce-21: Phase II Study of Vofatamab, a Selective Inhibitor of FGFR3, as Salvage Therapy in Metastatic Urothelial Carcinoma

ASCO GU 2019: Radical Cystectomy is the Best Option for Muscle-Invasive Bladder Cancer

ASCO GU 2019: Multimodality Treatment in Challenging Cases of Urothelial Carcinoma: Case Panel Discussion

ASCO GU 2019: Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer

ASCO GU 2019: Immunotherapy Across Genitourinary Malignancies

ASCO GU 2019: TROPHY-u-01: A Phase II Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Patients with Advanced Urothelial Cancer after Progression on Platinum-Based Chemotherapy and/or Anti-PD-1/PD-L1 Checkpoint Inhibitor Therapy

ASCO GU 2019: Randomized Phase III Trial of Adjuvant Sequential Chemotherapy Plus Radiotherapy versus Adjuvant Radiotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy

ASCO GU 2019: Keynote 057: Phase II trial of Pembrolizumab for Patients with High-risk NMIBC Unresponsive to BCG: Updated Interim Results

ASCO GU 2019: Whole Genome and Transcriptome Analysis of Metastatic Adrenocortical Carcinoma

ASCO GU 2019: Efficacy and Safety Data of the ARAMIS Study, Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Patients

ASCO GU 2019: Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer

ASCO GU 2019: Randomized Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning

1
2
3
4
5
6
7
8